WASHINGTON UNIVERSITY SCHOOL OF MEDICINE

Eisai's investigational anti-MTBR tau antibody etalanetug (E2814) has been granted FDA Fast Track designation to expedite development for Alzheimer's disease treatment.

Reprieve Cardiovascular closed an oversubscribed $61 million Series B financing led by Deerfield Management to advance its intelligent decongestion management therapy for acute decompensated heart failure.

An international Phase I/II trial of WU-CART-007, a universal CAR-T cell therapy, demonstrated a 91% overall response rate in patients with relapsed or refractory T cell acute lymphoblastic leukemia and T cell lymphoblastic lymphoma.

WashU Medicine researchers found only 1% of Alzheimer's patients treated with lecanemab experienced severe side effects requiring hospitalization, confirming clinical trial safety data in a real-world setting.

An international Phase 3 trial shows pembrolizumab (Keytruda) added to standard therapy extends disease-free survival from 30 to 51.8 months in patients with locally advanced head and neck cancer.

People diagnosed with cannabis use disorder (CUD) face nearly triple the risk of death over five years compared to the general population, with a tenfold increase in suicide risk, according to a large Canadian study.

AI technology developed at Washington University can analyze sequential mammograms to identify subtle tissue changes, predicting breast cancer risk 2.3 times more accurately than standard methods.

Nutrition plays a vital role throughout the cancer journey, with different dietary strategies needed during active treatment versus survivorship and prevention phases.

Wren Laboratories has introduced NETest 2.0, an AI-enhanced liquid biopsy test featuring a 51-gene mRNA expression algorithm, achieving over 95% sensitivity in NET detection and 90% accuracy in identifying disease progression.

• One of the first U.S. patients to receive Leqembi (lecanemab) in 2020, Sue Bell's four-year treatment journey provides insights into the drug's real-world impact on Alzheimer's progression. • While Leqembi successfully clears beta-amyloid plaques and can slow disease progression, the $25,000-per-year treatment shows varying effectiveness among patients and does not restore lost cognitive function. • After four years of twice-monthly infusions, Sue Bell discontinued treatment as her condition progressed beyond the early stage where Leqembi provides optimal benefit.